MGRX Quote, Financials, Valuation and Earnings

GoodRx Holdings, Inc. has a net margin of -9048.46% compared to Mangoceuticals, Inc.'s net margin of 0.57%. Mangoceuticals, Inc.'s return on equity of -117.74% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.

Mangoceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $4.95 which suggests that it could grow by 75.53%. Given that GoodRx Holdings, Inc. has higher upside potential than Mangoceuticals, Inc., analysts believe GoodRx Holdings, Inc. is more attractive than Mangoceuticals, Inc..

Mangoceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.

Mangoceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mangoceuticals, Inc. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.

Mangoceuticals, Inc. quarterly revenues are $84.2K, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. Mangoceuticals, Inc.'s net income of -$7.6M is lower than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, Mangoceuticals, Inc.'s price-to-earnings ratio is -- while GoodRx Holdings, Inc.'s PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mangoceuticals, Inc. is 17.76x versus 1.29x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of -9048.46% compared to Mangoceuticals, Inc.'s net margin of 11.54%. Mangoceuticals, Inc.'s return on equity of -117.74% beat National Research Corp.'s return on equity of 61.55%.

Mangoceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mangoceuticals, Inc. has higher upside potential than National Research Corp., analysts believe Mangoceuticals, Inc. is more attractive than National Research Corp..

Mangoceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

Mangoceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 2.72% to investors and pays a quarterly dividend of $0.12 per share. Mangoceuticals, Inc. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Mangoceuticals, Inc. quarterly revenues are $84.2K, which are smaller than National Research Corp. quarterly revenues of $34.6M. Mangoceuticals, Inc.'s net income of -$7.6M is lower than National Research Corp.'s net income of $4M. Notably, Mangoceuticals, Inc.'s price-to-earnings ratio is -- while National Research Corp.'s PE ratio is 25.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mangoceuticals, Inc. is 17.76x versus 2.89x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of -9048.46% compared to Mangoceuticals, Inc.'s net margin of 9.46%. Mangoceuticals, Inc.'s return on equity of -117.74% beat Spok Holdings, Inc.'s return on equity of 10.88%.

Mangoceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 57.78%. Given that Spok Holdings, Inc. has higher upside potential than Mangoceuticals, Inc., analysts believe Spok Holdings, Inc. is more attractive than Mangoceuticals, Inc..

Mangoceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

Mangoceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.39% to investors and pays a quarterly dividend of $0.31 per share. Mangoceuticals, Inc. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

Mangoceuticals, Inc. quarterly revenues are $84.2K, which are smaller than Spok Holdings, Inc. quarterly revenues of $33.9M. Mangoceuticals, Inc.'s net income of -$7.6M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, Mangoceuticals, Inc.'s price-to-earnings ratio is -- while Spok Holdings, Inc.'s PE ratio is 16.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mangoceuticals, Inc. is 17.76x versus 1.98x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.